REG - Hikma Pharmaceutical - Annual Financial Report and Notice of AGM

Hikma PharmaceuticalsAnnouncement

16/03/2023 10:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230316:nRSP2238Ta&default-theme=true

RNS Number : 2238T  Hikma Pharmaceuticals Plc  16 March 2023

Hikma Pharmaceuticals PLC

2022 Annual Report and Accounts and Notice of 2023 Annual General Meeting

 

Hikma Pharmaceuticals PLC (the "Company") announces that, the Annual Report
and Accounts for the year ended 31 December 2022 (the "Annual Report") and the
Notice of the 2023 Annual General Meeting (the "Notice of AGM") are today
being made available to shareholders.

The Annual Report and Notice of AGM can be viewed or downloaded from the
Company's website at www.hikma.com/investors/2022-annual-report/
(http://www.hikma.com/investors/2022-annual-report/) .

In accordance with Listing Rule 9.6.1 copies of the Annual Report and Notice
of AGM have been submitted to the National Storage Mechanism and will shortly
be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

ENDS -

 

 

 

 

Enquiries

Hikma Pharmaceuticals PLC

 

Hussein
Arkhagha
+44 20 7399 2760

Chief Counsel and Company Secretary

16 March 2023

 

 

 

 

About Hikma

Hikma helps put better health within reach every day for millions of people
around the world. For more than 40 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
the United States (US), the Middle East and North Africa (MENA) and Europe,
and we use our unique insight and expertise to transform cutting-edge science
into innovative solutions that transform people's lives. We're committed to
our customers and the people they care for, and by thinking creatively and
acting practically, we provide them with a broad range of branded and
non-branded generic medicines. Together, our 8,700 colleagues are helping to
shape a healthier world that enriches all our communities. We are a leading
licensing partner, and through our venture capital arm, are helping bring
innovative health technologies to people around the world. For more
information, please visit: www.hikma.com
(https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2531421-1%26h%3D3823969217%26u%3Dhttp%253A%252F%252Fwww.hikma.com%252F%26a%3Dwww.hikma.com&data=02%7C01%7Cmellisa%40hikma.uk.com%7C997d2fa3727b41845d4308d7ecef5a5f%7C178c1a723d3c40afbaa754615303bcdc%7C0%7C0%7C637238385059390461&sdata=JoY1dcOqWcUS12nfDFqq49wlYgBsw3%2BZFmrlDQ4QNI0%3D&reserved=0)
.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSUNARROSUOAAR